Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced

Pablo Tolosa1, Juan Montes2, Eva Ciruelos1

  • 1Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; SOLTI Cancer Research Group, Barcelona, Spain.

Med (New York, N.Y.)
|September 13, 2025
PubMed